HUMAN PAPILLOMA VIRUS. PREVENTION OF HPV-ASSOCIATED DISEASES

High prevalence of sexually transmitted diseases among the population attracts attention of specialists in all countries due to frequent development of complications resulting in reproductive dysfunction. The article presents one of the urgent issues of modern medicine — papillomavirus infection, which is the most common sexually transmitted disease. 70–80% of the sexually active persons contract human papilloma virus at one point. HPV induces a broad range of oncological reproductive diseases, including cervical, vulvar, vaginal and anal cancer and anogenital condylomae, which are observed both in men and women. The only reliable method of preventing papillomavirus infection is vaccination. The authors present new data on the use of the quadrivalent vaccine, including a new immunization pattern for 9–14-years-old girls.

papillomavirus infection, human papilloma virus, cervical cancer, anogenital region, prevention, vaccination, quadrivalent vaccine, girls, adolescents

1. de Villiers E.-M., Fauquet C., Broker T.R., Bernard H.-U., zur Hausen H. Phylogenetic tree containing sequences of 118 papillomavirus types. Virology. 2004; 324: 17−24.

2. WHO/IVB Database, as at 29 September 2014.

3. Centers for Disease Control and Prevention (CDC). Genital HPV infection (fact sheet). Available at: cdc.gov/std/hpv/hpv-fact-sheet.pdf. Accessed November 11, 2011.

4. Hampl M. et al. Obstet Gynecol. 2006; 108: 1361–1368.

5. Castle P.E., Schiffman M., Herrero R., Hildesheim A., Rodriguez A.C., Bratti M.C. J Infect Dis. 2005; 191: 1808–1816.

6. Anhang R., Goodman A., Goldie S.J. CA: A Cancer. J Clin. 2004; 54: 248–259.

7. Forman D. et al. Vaccine. 2012; 30 (Suppl. 5): F12−23.

8. World Health Organization. Available at: http://www.who.int/whr/1995/media_centre/executive_summary1/en/index.htm

9. Greer C.E. et al. J Clin Microbiol. 1995; 33: 2058−2063.

10. Human papillomavirus and HPV vaccines: technical information for policy-makers and health professionals, 2007. World Health Organization website. Available at: http://whqlibdoc.who.int/hq/2007/WHO _IVB_07.05_eng.pdf

11. Health Protection Agency (HPA). Health Protect Rep. 2012; 6: 9−15. Available at: http://www.hpa.org.uk/HPR/archives/2012/hpr2212.pdf.

12. Palefsky J.M. Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women. J NatI Cancer Inst Monogr. 1998; 23: 15–18.

13. Palefsky J.M. et al. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis. 2001; 183 (3): 383–91.

14. Xi L.F. et al. Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. Cancer Res.1998; 58 (17): 3839–44.

15. Critchlow C.W. et al. Effect of HIV infection on the natural history of anal human papillomavirus infection. AIDS. 1998; 12 (10): 1177–84.

16. Aslamazyan L.K., Namazova L.S. Genital warts. The prevalence, etiology, treatment and prevention. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2008; 5 (5): 14–17.

17. Namazova L.S. A new vaccine that prevents cervical cancer. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2006; 3 (6): 55–57.

18. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C.D., Parkin D. Globocan-2008. Cancer Incidence and Mortality Worldwide. IARC CancerBase. Lyon, France. 2010; 10.

19. Rogovskaya S.I. Prevalence of HPV infection in Russia. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and vaccination. 2012; 1 (62).

20. Globocan-2010. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in World. Summary Report 2010. Accessed on 09/09/2012.

21. Munoz N., Mendez F., Posso H. et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004; 15: 2077–87.

22. Micali С., Nasca М.К., Innocenzi О., Schwaгtz R.A. PeniIe сапсег. J Ат Acad Оегmatol. 2006; 54 (3): 369–91.

23. Brown D.R. et al. J Clin Microbiol. 1999; 37: 3316–3322.

24. Gomberg M.A. Reasons enough. Meditsinskii vestnik = Medical Bulletin. 2014; 25 (674).

25. Instruktsiya po primeneniyu preparata Tservariks [Application on the drug Cervarix].

26. Instruktsiya po primeneniyu preparata Gardasil [Application on the drug Gardasil].

27. Tatochenko V.K. Immunoprofilaktika-2014 [Immunization 2014]. Moscow, Pediatr"", 2014.

28. Brown D. The clinical impact of cross-protection to non-vaccine HPV types. Presented at: 27th International Papillomavirus Conference; September 17–22, 2011. Berlin, Germany. 2011. Abstract P-18.13.

29. The Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet. 2007; 369: 1861–68.

30. The FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomized controlled trial. BMJ. 2010; 340: 3493.

31. Garland S.M. The Australian Experience With the Human Papillomavirus Vaccine. Clinical Therapeutics. 2014; 36 (1).

32. Donovan B. et al. Lancet Infect Dis. 2011; 11: 39–44.

33. Grulich A.E. et al. IPV 2011. Berlin. 2011. Abstract O-04.01.

34. Read T et al. Sex Transm Infect. 2011; 87 (7): 544−7.

35. Fairley et al. Sex Transm Infect. 2009; 85: 10.